Kyowa Kirin Co., Ltd. (TYO:4151)
Japan · Delayed Price · Currency is JPY | Market Cap | 1.22T +4.3% |
| Revenue (ttm) | 529.80B +7.4% |
| Net Income | 81.34B +111.7% |
| EPS | 155.37 +112.1% |
| Shares Out | 523.59M |
| PE Ratio | 14.98 |
| Forward PE | 13.70 |
| Dividend | 70.00 (3.01%) |
| Ex-Dividend Date | Dec 29, 2026 |
| Volume | 1,714,400 |
| Open | 2,350.00 |
| Previous Close | 2,342.00 |
| Day's Range | 2,312.50 - 2,355.50 |
| 52-Week Range | 2,109.00 - 2,912.00 |
| Beta | 0.22 |
| Analysts | Sell |
| Price Target | 2,263.64 (-2.76%) |
| Earnings Date | Nov 2, 2026 |
About Kyowa Kirin
Kyowa Kirin Co., Ltd. engages in the research, development, manufacturing, and marketing of pharmaceuticals in Japan, the Americas, Europe, Asia, and internationally. The company offers Ziftomenib, an oral menin inhibitor for the treatment of adult relapsed or refractory and acute myeloid leukemia with a nucelophosmin1 mutation; and Lumicef for the treatment of palmoplantar pustulosis. It also develops KHK4083/AMG 451 rocatinlimab, which is in Phase III clinical trial for the treatment of moderate to severe atopic dermatitis and prurigo nodular... [Read more]
Financial Performance
In 2025, Kyowa Kirin's revenue was 496.83 billion, an increase of 0.26% compared to the previous year's 495.56 billion. Earnings were 67.04 billion, an increase of 11.98%.
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for 4151 stock is "Sell." The 12-month stock price target is ¥2,264, which is a decrease of -2.76% from the latest price.
News
Kyowa Kirin Reports Three-Year Real-World Data On Burosumab In Adults With XLH
(RTTNews) - Kyowa Kirin, Inc., a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (KYKOY), announced the publication of three-year real-world findings comparing burosumab with oral phosphate and activ...
Kyowa Kirin, Knight Therapeutics Enter Distribution Deal For POTELIGEO In Latin America
(RTTNews) - Tuesday, Kyowa Kirin (4151.T) said it entered into an exclusive distribution agreement with Knight Therapeutics (GUD.TO) for POTELIGEO (mogamulizumab) in select Latin American countries.
Knight Therapeutics, Kyowa Kirin enter distribution agreement for POTELIGEO
Kyowa Kirin International (KYKOF) announced the signing of an exclusive distribution agreement with Knight Therapeutics (KHTRF) for the distribution of mogamulizumab in select countries in Latin Ameri...
Kyowa Kirin and Knight Therapeutics Enter Into Exclusive Distribution Agreement for POTELIGEO® (mogamulizumab) for Cutaneous T-Cell Lymphoma (CTCL) Patients Across Latin America
GALASHIELS & MARLOW, U.K.--(BUSINESS WIRE)--Kyowa Kirin International, a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), today announced the signing of an exclusive distribut...
Knight Therapeutics signs exclusive distribution agreement with Kyowa Kirin
Knight Therapeutics (KHTRF) announced the signing of an exclusive distribution agreement with Kyowa Kirin International, a wholly owned subsidiary of Kyowa Kirin (KYKOF), a Japan-based global specialt...
Kyowa Kirin Slides: Investor presentation
Kyowa Kirin has posted slides in relation to its latest quarterly earnings report, which was published on September 9, 2026.
Kyowa Kirin downgraded to Hold from Buy at Jefferies
Jefferies downgraded Kyowa Kirin (KYKOF) to Hold from Buy with a price target of 2,600 yen, down from 2,800 yen, following “disappointing” Phase 2 data for ophthalmology candidate KHK4951. Following…
Trump Administration Reaches Drug Pricing Deals With 9 Companies
The agreements provide for all state Medicaid programs to pay prices for prescription drugs that match the lowest prices paid by other developed nations, the White House said
Kyowa Kirin Quarterly report: Q2 2026
Kyowa Kirin has published its Q2 2026 quarterly earnings report on August 3, 2026.
Kyowa Kirin Slides: Q2 2026
Kyowa Kirin has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 3, 2026.
The XLH Network and Kyowa Kirin Launch the XLH Community Guidebook to Help People Navigate Lifelong Journey with XLH
New online resource brings together practical information, community perspectives, and expert guidance tailored to people with XLH across ages and life stages New online resource brings together pract...
Kyowa Kirin to Present New Complementary Evidence Further Defining Clinical Utility of Mogamulizumab in Cutaneous T-Cell Lymphoma at 2026 WCCL
New Clinical Data, Patient Reported Outcomes, Real-World Utilization, and Comparative-Effectiveness Models to be Featured in Four Oral and One Poster Presentation New Clinical Data, Patient Reported O...
Kura, Kyowa Kirin to present updated frontline data from Phase 1 KOMET-007 trial
Kura Oncology, (KURA) and Kyowa Kirin (KYKOF) announced that updated results from the frontline arm of the Phase 1 KOMET-007 clinical trial evaluating ziftomenib in combination with cytarabine plus da...
Kyowa Kirin Quarterly report: Q1 2026
Kyowa Kirin has published its Q1 2026 quarterly earnings report on May 7, 2026.
Kyowa Kirin Slides: Q1 2026
Kyowa Kirin has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 7, 2026.
Kyowa Kirin downgraded to Sell from Buy at Citi
Citi downgraded Kyowa Kirin (KYKOF) to Sell from Buy with a 2,000 yen price target
Kyowa Kirin downgraded to Underweight from Equal Weight at Morgan Stanley
Morgan Stanley analyst Shinichiro Muraoka downgraded Kyowa Kirin (KYKOF) to Underweight from Equal Weight with a 1,700 yen price target
Kyowa Kirin downgraded to Neutral from Outperform at SMBC Nikko
SMBC Nikko downgraded Kyowa Kirin (KYKOF) to Neutral from Outperform with a 2,200 yen price target
Kyowa Kirin downgraded to Underweight from Neutral at JPMorgan
JPMorgan downgraded Kyowa Kirin (KYKOF) to Underweight from Neutral with a price target of 1,800 yen, down from 2,300 yen. The company announced it will discontinue all clinical trials for…
Kyowa Kirin stops development of skin condition treatment
Kyowa Kirin on Tuesday said it is discontinuing all ongoing trials of its experimental drug to treat skin conditions.
Kyowa Kirin announces discontinuation of rocatinlimab clinical trials
Kyowa Kirin (KYKOF) announced the discontinuation of all ongoing clinical trials for rocatinlimab, an investigational anti-OX40 monoclonal antibody being evaluated for potential indications in moderat...
Kyowa Kirin Quarterly report: Q4 2025
Kyowa Kirin has published its Q4 2025 quarterly earnings report on February 9, 2026.
Kyowa Kirin Slides: Q4 2025
Kyowa Kirin has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 9, 2026.
Kyowa Kirin Slides: Investor presentation
Kyowa Kirin has posted slides in relation to its latest quarterly earnings report, which was published on February 1, 2026.
Kyowa Kirin to regain control of rocatinlimab development, commercialization
Kyowa Kirin (KYKOF) announced the termination of the current rocatinlimab development and commercialization collaboration with Amgen. Kyowa Kirin will regain control of the global rocatinlimab program...